{"analyses":[{"groupDescription":"6-8 weeks","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.39","pValueComment":"One-side significance level = 0.05","statisticalMethod":"Chi-squared"},{"groupDescription":"1 year","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.78","pValueComment":"One-side significance level = 0.05","statisticalMethod":"Chi-squared"},{"groupDescription":"2 years","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.28","pValueComment":"One-side significance level = 0.05","statisticalMethod":"Chi-squared"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"33","upperLimit":"60","value":"46"},{"groupId":"OG001","lowerLimit":"26","upperLimit":"51","value":"38"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"56"}],"units":"Participants"}],"title":"6-8 weeks from end of treatment"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"26","upperLimit":"53","value":"39"},{"groupId":"OG001","lowerLimit":"27","upperLimit":"58","value":"42"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"36"}],"units":"Participants"}],"title":"1 year from start of treatment"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"23","upperLimit":"61","value":"41"},{"groupId":"OG001","lowerLimit":"14","upperLimit":"45","value":"27"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"30"}],"units":"Participants"}],"title":"2 years from start of treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"83"}],"units":"Participants"}],"description":"The ECS is a 17-item self-report instrument designed to measure multidimensional quality of life in patients with esophagus cancer with a total score ranging from 0-68. It is to be administered with the Functional Assessment of Cancer Therapy - General (FACT-G). A higher score indicates better QOL. Improvement is defined as an increase from the baseline score of at least 5 points.","dispersionType":"95% Confidence Interval","groups":[{"description":"Radiation therapy with concurrent trastuzumab, paclitaxel, and carboplatin followed by surgery followed by maintenance trastuzumab","id":"OG000","title":"Chemoradiation and Trastuzumab"},{"description":"Radiation therapy with concurrent paclitaxel and carboplatin followed by surgery","id":"OG001","title":"Chemoradiation"}],"paramType":"NUMBER","populationDescription":"Eligible participants who consented to quality of life evaluation and who had baseline and time point data.","reportingStatus":"POSTED","timeFrame":"Baseline, 6-8 weeks after end of radiation therapy (approximately 11.5-13.5 weeks from treatment start), 1 and 2 years from treatment start","title":"Percentage of Patients With Improvement in the Functional Assessment of Cancer Therapy - Esophagus (FACT-E) Esophageal Cancer Subscale (ECS) Subscale After Treatment","type":"SECONDARY","unitOfMeasure":"percentage of participants"}